

**SUPPLEMENTAL DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention | **PLATELET ADP RECEPTOR INHIBITORS**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 09/920,325, filed on August 2, 2001,
which is a CIP of 09/775,812, Filed 02/05/01 (now abandoned)
and is a CIP of PCT/US01/03585, Filed 02/05/01
- ☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor 1 Robert M. Scarborough Date: 9-16-03

Signature:  Citizen of: United States

Inventor 2 Wolin Huang Date: _____

Signature: _____ Citizen of: United States

Inventor 3 Charles K. Marlowe Date: _____

Signature: _____ Citizen of: United States

Inventor 4 Kim A. Kane-MaGuire Date: _____

Signature: _____ Citizen of: United States

☐ Additional inventors are being named on additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**SUPPLEMENTAL DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention | **PLATELET ADP RECEPTOR INHIBITORS**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 09/920,325, filed on August 2, 2001,
which is a CIP of 09/775,812, Filed 02/05/01 (now abandoned),
and is a CIP of PCT/US01/03585, Filed 02/05/01
- ☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor 1 Robert M. Scarborough Date: _____

Signature: _____ Citizen of: United States

Inventor 2 Wolin Huang Date: Oct 2, 2003

Signature: Wolin Huang Citizen of: United States

Inventor 3 Charles K. Marlowe Date: _____

Signature: _____ Citizen of: United States

Inventor 4 Kim A. Kane-MaGuire Date: _____

Signature: _____ Citizen of: United States

☐ Additional inventors are being named on additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**SUPPLEMENTAL DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention **PLATELET ADP RECEPTOR INHIBITORS**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 09/920,325, filed on August 2, 2001,
which is a CIP of 09/775,812, Filed 02/05/01 (now abandoned)
and is a CIP of PCT/US01/03585, Filed 02/05/01
- ☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;


I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor 1 Robert M. Scarborough Date: _____
Signature: _____ Citizen of: United States

Inventor 2 Wolin Huang Date: _____
Signature: _____ Citizen of: United States

Inventor 3 Charles K. Marlowe Date: 9-22-03
Signature:  Citizen of: United States

Inventor 4 Kim A. Kane-MaGuire Date: _____
Signature: _____ Citizen of: United States

☐ Additional inventors are being named on additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1460, Alexandria, VA 22313-1460. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O.

**SUPPLEMENTAL DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION
USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

Title of Invention | **PLATELET ADP RECEPTOR INHIBITORS**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 09/920,325, filed on August 2, 2001,
which is a CIP of 09/775,812, Filed 02/05/01 (now abandoned)
and is a CIP of PCT/US01/03585, Filed 02/05/01
- ☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor 1	<u>Robert M. Scarborough</u>	Date:	_____
Signature:	_____	Citizen of:	<u>United States</u>
<hr/>			
Inventor 2	<u>Wolin Huang</u>	Date:	_____
Signature:	_____	Citizen of:	<u>United States</u>
<hr/>			
Inventor 3	<u>Charles K. Marlowe</u>	Date:	_____
Signature:	_____	Citizen of:	<u>United States</u>
<hr/>			
Inventor 4	<u>Kim A. Kane-Maguire</u>	Date:	<u>10/2/2003</u>
Signature:	<u>Kim A. Kane-Maguire</u>	Citizen of:	<u>United States</u>

☐ Additional inventors are being named on _____ additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Robert M. Scarborough, Wolin Huang, Charles K. Marlowe and Kim A. Kane-MaGuire

Application No./Patent No.: 09/920,325

Filed/Issue Date: August 2, 2001

Entitled: PLATELET ADP RECEPTOR INHIBITORS

Millennium Pharmaceuticals, Inc. a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by: percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Robert M. Scarborough et al. To: Cor Therapeutics, Inc.

The document was recorded in the United States Patent and Trademark Office at
Reel 012010, Frame 0811, or for which a copy thereof is attached.

2. Merger of: Cor Therapeutics, Inc. Into: Millennium Pharmaceuticals, Inc.

A copy of the Certificate of Merger is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee:

Oct. 17, 2003

Date

Robert Silverman

Typed or printed name

R Silver

Signature

Assoc. General Counsel

Title

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"COR THERAPEUTICS, INC.", A DELAWARE CORPORATION,
WITH AND INTO "MILLENNIUM PHARMACEUTICALS, INC." UNDER THE NAME OF "MILLENNIUM PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWELFTH DAY OF FEBRUARY, A.D. 2002, AT 6 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

2322355 8100M


AUTHENTICATION: 1610075

020093846

DATE: 02-12-02


Commonwealth of Massachusetts)
)ss.
County of Middlesex)

I, Joel S. Goldberg, hereby swear that the attached reproduction of the Certificate of Ownership and Merger Merging COR Therapeutics, Inc. (a Delaware corporation) into Millennium Pharmaceuticals, Inc. (a Delaware corporation) dated February 12, 2002, is a true, correct and complete photocopy of a document in my possession.



Joel S. Goldberg
Counsel
Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139

Subscribed and sworn to before me this 14th day of May, 2002 by Joel S. Goldberg.



Jean L. Ernst
Notary Public
My commission expires: August 15, 2008

(Seal)

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

COR THERAPEUTICS, INC.
(a Delaware corporation)

INTO

MILLENNIUM PHARMACEUTICALS, INC.
(a Delaware corporation)

Millennium Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "Corporation"), does hereby certify:

FIRST: That the Corporation was incorporated on the 13th day of January, 1993, pursuant to the General Corporation Law of the State of Delaware.

SECOND: That the Corporation owns all of the outstanding shares of each class of the stock of COR Therapeutics, Inc., a corporation incorporated on the 4th day of February, 1988 pursuant to the General Corporation Law of the State of Delaware.

THIRD: That the Board of Directors of the Corporation, by written action in lieu of a meeting dated the 4th day of February, 2002, duly adopted the following resolutions:

RESOLVED: That, pursuant to Section 253 of the Delaware General Corporation Law, the Corporation is hereby authorized to merge COR Therapeutics, Inc., a Delaware corporation which is a wholly owned subsidiary of the Corporation, into the Corporation;

RESOLVED: That the President and Secretary of the Corporation be, and each of them hereby is, authorized to execute a Certificate of Ownership and Merger with respect to the merger of COR Therapeutics, Inc. into the Corporation, cause the same to be filed with the Secretary of State of the State of Delaware and take all such other actions and to execute all such other instruments and agreements as the officer or officers so acting may deem appropriate to effect such merger;

RESOLVED: That the merger of COR Therapeutics, Inc. into the Corporation shall be effective upon the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate to be signed by its authorized officer this 12th day of February, 2002.

MILLENNIUM
PHARMACEUTICALS, INC.

By: 

Title: Chairperson, Chief Executive
Officer and President

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"PGM CORPORATION", A DELAWARE CORPORATION,
WITH AND INTO "COR THERAPEUTICS, INC." UNDER THE NAME OF
"COR THERAPEUTICS, INC.", A CORPORATION ORGANIZED AND EXISTING
UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED
IN THIS OFFICE THE TWELFTH DAY OF FEBRUARY, A.D. 2002, AT 1:30
O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF
THE AFORESAID CERTIFICATE OF MERGER IS THE TWELFTH DAY OF
FEBRUARY, A.D. 2002, AT 4:01 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE
KENT COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State


2151084 8100M

020092095


AUTHENTICATION: 1609158

Commonwealth of Massachusetts)
)ss.
County of Middlesex)

I, Joel S. Goldberg, hereby swear that the attached reproduction of the Certificate of Merger of PGM Corporation (a Delaware corporation) into COR Therapeutics, Inc. (a Delaware corporation) dated February 12, 2002, is a true, correct and complete photocopy of a document in my possession.


Joel S. Goldberg
Counsel
Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, Massachusetts 02139

Subscribed and sworn to before me this 14th day of May, 2002 by Joel S. Goldberg.


Jean L. Ernst
Notary Public
My commission expires: August 15, 2008

(Seal)

CERTIFICATE OF MERGER**OF****PGM CORPORATION**
(a Delaware corporation)**INTO****COR THERAPEUTICS, INC.**
(a Delaware corporation)

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 01:30 PM 02/12/2002
020092095 - 2151084

COR Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify:

FIRST: That the name and state of incorporation of each of the constituent corporations of the merger is as follows:

<u>Name</u>	<u>State of Incorporation</u>
PGM Corporation	Delaware
COR Therapeutics, Inc.	Delaware

SECOND: That an Agreement and Plan of Merger, dated December 5, 2001, by and among Millennium Pharmaceuticals, Inc., a Delaware corporation, PGM Corporation and COR Therapeutics, Inc. setting forth the terms and conditions of the merger of PGM Corporation with and into COR Therapeutics, Inc. has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with the requirements of Subsection (c) of Section 251 of the General Corporation Law of the State of Delaware.

THIRD: That the name of the surviving corporation of the merger is COR Therapeutics, Inc.

FOURTH: That the Restated Certificate of Incorporation of COR Therapeutics, Inc., a Delaware corporation which will survive the merger, shall be the Restated Certificate of Incorporation of the surviving corporation, and shall be amended so that Article FOURTH of such Restated Certificate of Incorporation reads in its entirety as follows:

"FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is 1,000, all of which shall consist of common stock, \$.01 par value per share."

FIFTH: That the executed Agreement and Plan of Merger is on file at the principal place of business of the surviving corporation. The address of said principal place of business is COR Therapeutics, Inc., 256 E. Grand Avenue, South San Francisco, California, 94080.

SIXTH: That a copy of the Agreement and Plan of Merger will be furnished by the surviving corporation upon request and without cost to any stockholder of any constituent corporation.

SEVENTH: That this Certificate of Merger shall be effective as of 4:01 p.m. Eastern Standard Time on February 12, 2002.

IN WITNESS WHEREOF, COR Therapeutics, Inc. has caused this Certificate to be executed by its President and Chief Executive Officer and attested by its Secretary this 12th day of February, 2002.

COR THERAPEUTICS, INC.

(a Delaware corporation)

By: /s/ Vaughn M. Kailian

Vaughn M. Kailian

President and

Chief Executive Officer

Dated: February 12, 2002

ATTEST:

/s/ Patrick A. Broderick

Patrick A. Broderick

Secretary